text
"['\n2. 주요 제품 및 서비스\n1) 주요 제품 등의 현황(연결기준)\n(단위 : 천원 %)\n사업부문\n매출유형\n품\xa0\xa0 목\n구체적용도\n주요상표등\n매출액\n비율\n의약품\n제\xa0 품\n\xa0넥실렌\xa0\n급성위염, 만성위염\n7,291,577\n1.4\n\xa0란스톤 캡슐\xa0\n활동성십이지장궤양\n4,863,753\n0.9\n클로피린 캡슐\n급성관상동맥증후군 개선\n5,696,142\n1.1\n\xa0티에스원 캡슐\xa0\n위암,두경부암,결장,직장암\n4,370,128\n0.8\n\xa0스타브론 정\xa0\n우울증\n4,410,507\n0.8\n\xa0비유피-4정\xa0\n빈뇨,뇨실금\n4,629,551\n0.9\n\xa0크라비트주\xa0\n광범위 항생제\n2,975,968\n0.6\n\xa0옴니세프\xa0\n전연성농가진\n2,457,767\n0.5\n베라실\n만성동맥폐색증에 따른 궤양\n3,575,928\n0.7\n필그렐정\n죽상동맥경화성 증상의 개선\n4,690,809\n0.9\n\xa0야마테탄 주\xa0\n패혈증\n2,045,498\n0.4\n크라비트정\n광범위 항생제\n2,098,844\n0.4\n\xa0기타\n-\n53,988,726\n10.2\n상\xa0 품\n\xa0리피토 정\xa0\n고지혈증\n131,520,160\n24.9\n\xa0리리카 캡슐\xa0\n말초신경병성\n50,877,923\n9.6\n\xa0쎄레브렉스 캡슐\n해열,진통소염제\n35,726,985\n6.8\n\xa0란스톤 LFDT 정\xa0\n활동성십이지장궤양\n23,051,673\n4.4\n\xa0뉴론틴 캡슐\xa0\n신경병성통증\n17,878,872\n3.4\n\xa0액토스\xa0\n당뇨\n16,436,052\n3.1\n\xa0카듀엣 정\xa0\n고혈압\n13,984,208\n2.6\n덱실란트 디알캡슐\n\xa0미란성 식도염의 치료\n13,825,416\n2.6\n네시나\n당뇨\n24,568,725\n4.7\n기타\n-\n94,583,404\n17.9\n기\xa0 타\n수탁시험외\n-\n2,123,089\n0.4\n합\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 계\n527,671,705\n100.0\n2) 주요 제품 등의 가격변동추이\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 (단위: 원)\n품\xa0 목\n제5기 3분기\n제4기\n제3기\n\xa0란스톤 30mg 28C\n14,388\n15,050\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 14,554\n\xa0크라비트주 250mL\n4,551\n4,336\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 4,744\n\xa0옴니세프 100mL 500C\n124,415\n168,121\n\xa0 \xa0 \xa0 \xa0 \xa0 175,365\n\xa0티에스원 20mg 56C\n150,380\n150,024\n\xa0 \xa0 \xa0 \xa0 \xa0 151,500\n\xa0뉴론틴 300mg 200C\n60,397\n60,165\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 61,128\n\xa0리리카 75mg 30C\n12,979\n12,985\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 13,075\n\xa0리피토 정 10mg 90 T\n48,056\n48,033\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 48,263\n']"
